Cargando…
Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer
BACKGROUND: A patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421611/ https://www.ncbi.nlm.nih.gov/pubmed/28334914 http://dx.doi.org/10.1093/jjco/hyx019 |
_version_ | 1783234612502200320 |
---|---|
author | Masuda, Kenta Hirasawa, Akira Irie-Kunitomi, Haruko Akahane, Tomoko Ueki, Arisa Kobayashi, Yusuke Yamagami, Wataru Nomura, Hiroyuki Kataoka, Fumio Tominaga, Eiichiro Banno, Kouji Susumu, Nobuyuki Aoki, Daisuke |
author_facet | Masuda, Kenta Hirasawa, Akira Irie-Kunitomi, Haruko Akahane, Tomoko Ueki, Arisa Kobayashi, Yusuke Yamagami, Wataru Nomura, Hiroyuki Kataoka, Fumio Tominaga, Eiichiro Banno, Kouji Susumu, Nobuyuki Aoki, Daisuke |
author_sort | Masuda, Kenta |
collection | PubMed |
description | BACKGROUND: A patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and the rates of patients that meet the Society of Gynecologic Oncology criteria in ovarian cancer and endometrial cancer patients. METHOD: Ovarian or endometrial cancer patients were recruited for this study. After informed consent was obtained, participants completed the questionnaire. Genetic risks were assessed from the data of each patient's questionnaire by Society of Gynecologic Oncology guideline. Clinical and pathological findings were compared between the genetic risk groups. RESULTS: A total of 105 patients were identified with ovarian cancer and 56 patients with endometrial cancer eligible for this study. According to the Society of Gynecologic Oncology guideline, of the 105 ovarian cancer patients, 25 patients (23%) had a 20–25% risk and three patients (2.9%) had a 5–10% risk of hereditary breast and ovarian cancer syndrome. A further 22 patients (21%) had a 5–10% risk of Lynch syndrome. Two patients (1.9%) met the Amsterdam criteria II. Of 56 endometrial cancer patients, 24 patients (42.9%) had a 5–10% risk of Lynch syndrome. The endometrial cancer patients with genetic risk of Lynch syndrome were younger (mean age: 47.79) at diagnosis compared to patients without a genetic risk of Lynch syndrome (mean age: 57.91). CONCLUSIONS: In this study, we were able to show that the newly designed questionnaire is a useful tool for evaluating cancer family history along with Society of Gynecologic Oncology criteria or Amsterdam criteria II. When considering the risk of Lynch syndrome for a patient with ovarian cancer, it is important to collect a second and third relative's family history. |
format | Online Article Text |
id | pubmed-5421611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54216112017-05-11 Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer Masuda, Kenta Hirasawa, Akira Irie-Kunitomi, Haruko Akahane, Tomoko Ueki, Arisa Kobayashi, Yusuke Yamagami, Wataru Nomura, Hiroyuki Kataoka, Fumio Tominaga, Eiichiro Banno, Kouji Susumu, Nobuyuki Aoki, Daisuke Jpn J Clin Oncol Original Article BACKGROUND: A patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and the rates of patients that meet the Society of Gynecologic Oncology criteria in ovarian cancer and endometrial cancer patients. METHOD: Ovarian or endometrial cancer patients were recruited for this study. After informed consent was obtained, participants completed the questionnaire. Genetic risks were assessed from the data of each patient's questionnaire by Society of Gynecologic Oncology guideline. Clinical and pathological findings were compared between the genetic risk groups. RESULTS: A total of 105 patients were identified with ovarian cancer and 56 patients with endometrial cancer eligible for this study. According to the Society of Gynecologic Oncology guideline, of the 105 ovarian cancer patients, 25 patients (23%) had a 20–25% risk and three patients (2.9%) had a 5–10% risk of hereditary breast and ovarian cancer syndrome. A further 22 patients (21%) had a 5–10% risk of Lynch syndrome. Two patients (1.9%) met the Amsterdam criteria II. Of 56 endometrial cancer patients, 24 patients (42.9%) had a 5–10% risk of Lynch syndrome. The endometrial cancer patients with genetic risk of Lynch syndrome were younger (mean age: 47.79) at diagnosis compared to patients without a genetic risk of Lynch syndrome (mean age: 57.91). CONCLUSIONS: In this study, we were able to show that the newly designed questionnaire is a useful tool for evaluating cancer family history along with Society of Gynecologic Oncology criteria or Amsterdam criteria II. When considering the risk of Lynch syndrome for a patient with ovarian cancer, it is important to collect a second and third relative's family history. Oxford University Press 2017-05 2017-02-23 /pmc/articles/PMC5421611/ /pubmed/28334914 http://dx.doi.org/10.1093/jjco/hyx019 Text en © The Author 2017. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Masuda, Kenta Hirasawa, Akira Irie-Kunitomi, Haruko Akahane, Tomoko Ueki, Arisa Kobayashi, Yusuke Yamagami, Wataru Nomura, Hiroyuki Kataoka, Fumio Tominaga, Eiichiro Banno, Kouji Susumu, Nobuyuki Aoki, Daisuke Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer |
title | Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer |
title_full | Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer |
title_fullStr | Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer |
title_full_unstemmed | Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer |
title_short | Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer |
title_sort | clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421611/ https://www.ncbi.nlm.nih.gov/pubmed/28334914 http://dx.doi.org/10.1093/jjco/hyx019 |
work_keys_str_mv | AT masudakenta clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT hirasawaakira clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT iriekunitomiharuko clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT akahanetomoko clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT uekiarisa clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT kobayashiyusuke clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT yamagamiwataru clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT nomurahiroyuki clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT kataokafumio clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT tominagaeiichiro clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT bannokouji clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT susumunobuyuki clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer AT aokidaisuke clinicalutilityofaselfadministeredquestionnaireforassessmentofhereditarygynecologiccancer |